Reading Room Production — page 14
of 496 pages
← p.13 p.15 → · this page in the original PDF · package
ing
ot
(Db
>E2 Expressing Mice with
on experiments as described
this occurred?
Wuhan University and that humanized mice will be bread at University of Wuhan and UNC - CH. Furthermore, the mice
will be inoculated with the virus. Under "UNC Facilities where selected agents to be used" it continues with all mouse
studies at UNC-CH will be performed...." However, on page 200 of the same SF 424 there is a letter from UNC - CH stating
"The work to be performed by UNC-CH does not include animal and/or human research subjects." I know that was a lot
of information but where exactly was the experimentation of injecting the humanized mice with the recombinant DNA
occurring?
SF 424 AI110964-01 (received date 06/05/2013)
In this SF 424 Aim 3 seems indicative of gain of function experimentation (C3a and C3b) although it does not use that
exact term. On page 119 of AI110964-01 under "C3d) Humanized mouse in vivo infection experiments" it states that
humanized mouse in vivo experiments in humanized mice was occurring at the Wuhan Institute of Virology. I did not see
the location where these gain of function experiments were being done but if the injections were occurring at WIV then
was the recombinant DNA also generated at WIV? Was Seemless Cloning also being done?
RPPR (AI110964-05)
Finally, in the RPPR (6/1/2017-5/31/2018) on page 28 under "In Vivo Infection of Human ACE2 Expressing Mice with
SARSr-Cov S Protein variants", it appears to be showing the results from their gain of function experiments as described
in the SF 424. This is more of less the same as the question above, but do you know where this occurred?
This is our OCR of the page, with running headers and footers removed. The
Committee's PDF
is authoritative; quote from it. Machine-readable, including the uncleaned
text: /api/page/reading_room/14
Records on this page
| Record | Date | Type | Pages |
|---|---|---|---|
| Grant Questions - FBI Inquiry - 1-R01AI110964-01 - 2-R01AI110964-06 | 2020-05-13 | 13–15 |